organic lesion | structural lesion

gross lesion [ macroscopical lesion | macroscopic lesion ]

Commission des lésions professionnelles [ CLP | Commission d'appel en matière de lésions professionnelles ]

California meadow nematode [ California root-lesion nematode | California lesion nematode | Pratylenchus neglectus ]

lesion topography | topography of the lesions

lesion nematode | meadow nematode | northern root lesion nematode

dermal lesion | skin lesion

joint lesions due to caisson disease | joint lesions due to pneumatic tools

Modifiers The following fourth-character subdivisions classify morphological changes and are for use with categories N00-N07. Subdivisions .0-.8 should not normally be used unless these have been specifically identified (e.g. by renal biopsy or autopsy). The three-character categories relate to clinical syndromes. Code Title .0 Minor glomerular abnormality Minimal change lesion .1 Focal and segmental glomerular lesions Focal and segmental:hyalinosis | sclerosis | Focal glomerulonephritis .2 Diffuse membranous glomerulonephritis .3 Diffuse mesangial proliferative glomerulonephritis .4 Diffuse endocapillary proliferative glomerulonephritis ...[+++] .5 Diffuse mesangiocapillary glomerulonephritis Membranoproliferative glomerulonephritis, types 1 and 3, or NOS .6 Dense deposit disease Membranoproliferative glomerulonephritis, type 2 .7 Diffuse crescentic glomerulonephritis Extracapillary glomerulonephritis .8 Other Proliferative glomerulonephritis NOS .9 Unspecified | Minimal change lesion | Focal and segmental:hyalinosis | sclerosis | Focal glomerulonephritis | Membranoproliferative glomerulonephritis, types 1 and 3, or NOS | Membranoproliferative glomerulonephritis, type 2 | Extracapillary glomerulonephritis | Proliferative glomerulonephritis NOS

So I don't think it's an issue of how our ethics committees would be structured to oversee the process of intervention of the venous lesions described by Dr. Zamboni.

A person with a structural intra-cerebral lesion who has increased risk of seizures should not be able to drive vehicles of group 2 until the epilepsy risk has fallen to at least 2 % per annum.

The decision on whether carcinogenicity testing is required shall take into account the results of genotoxicity tests, structure-activity relationships and the findings in systemic toxicity tests that may be relevant to neoplastic lesions in longer term studies.

The decision on whether carcinogenicity testing is required shall take into account the results of genotoxicity tests, structure-activity relationships and the findings in systemic toxicity tests that may be relevant to neoplastic lesions in longer term studies.